URGN — UroGen Pharma Ltd.
URGN dilution and offerings
- Active shelf: S-3ASR (Nov 2025)
- Float: 37.0M shares
$32.72-2.27%
Last close: · regular session
Last 60 sessions
Active automatic shelf (S-3ASR, Nov 2025). Float: 37.0M shares. Latest SEC filing: 8-K on Aug 20, 2026. URGN closed at $32.72 (-2.27%) on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for URGN in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 234
- Website: https://www.urogen.com
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Latest SEC filings for URGN
Latest URGN news
- UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer Read article
- UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 Read article
- UroGen gets FDA review for new bladder cancer therapy Read article
- UroGen Pharma: An Emerging GARP Stock Read article
- Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.